Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 12 (2003), Issue 2, Pages 123-125
http://dx.doi.org/10.1080/0962935031000097736

Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index

1Dipartimento di Medicina Clinica e delle Patologie Emergenti, Università degli Studi di Palermo, Italy
2Dipartimento di Patologia Umana, Università degli Studi di Messina, Italy
3Dipartimento di Medicina Sociale Territoriale, Università degli Studi di Messina, Italy
4Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Verona, Sezione B – Policlinico GB Rossi, Piazzale Scuro 10, Verona 37134, Italy

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The value of CD30 and the soluble circulating fragment of CD30 (sCD30) for atopic dermatitis (AD) remains unclear. In particular, little is known about the effects of age, duration of disease and Scoring Atopic Dermatitis index (SCORAD) on the levels of serum sCD30 in patients affected by AD. In the present study, we have analysed serum sCD30 levels of adult patients affected by AD. The study's population includes 18 non-smoking outpatients, with a diagnosis of AD. As a control group we studied 18 non-atopic subjects from laboratory staff, matched for sex and age. These subjects had no history of AD, urticaria or seasonal or perennial rhinitis or asthma, and had negative skin prick test to a panel of allergens.

The sCD30 serum levels were clearly higher in patients affected by AD (14.2±9.0 IU/ml) than in healthy subjects (1.2±0.8 IU/ml) (P<0.001). No differences were observed between males and females affected by atopic dermatitis, regarding age, duration of disease and SCORAD. Significant correlations were found between serum levels of sCD30 levels and age (r=0.55; 95% confidence interval (CI) for r (Fisher's z transformed)=−0.81 to −0.12;P=0.01), duration of the disease (months) (r=0.64; 95% CI for r (Fisher's z transformed)=−0.85 to −0.24; P=0.004) and SCORAD r=0.74; 95% CI for r (Fisher's z transformed)=−0.89 to −0.42; P=0.004).

As demonstrated by the close correlation with age, duration of disease and SCORAD, serum levels of sCD30 appear to be an additional marker for the follow-up of AD.